

Performance in Delivering Qtr 4 2018-19

Id	Research Ethics Committee Reference Number	Integrated Research Application System Number	Name of Trial	Target Number Of Patients Agreed?	Minimum Number Of Patients Agreed (Enter Same In Both If Only One Number)	Maximum Number Of Patients Agreed (Enter Same In Both If Only One Number)	Target Date To Recruit Patients Agreed?	Date Agreed to recruit target number of patients	Total Number Of Patients Recruited At The Agreed Target Date	Date That The Trial Closed To Recruitment	Total Number Of Study Participants Recruited	Reason For Closure Of Trial	Comments
37452	16/EM/0133	184873	A randomized, double-blind, placebo-controlled multicenter study of secukinumab to evaluate the safety, tolerability and efficacy up to 2 years in patients with active nonradiographic axial spondyloarthritis	Number Agreed	3	3	Date Agreed	29/06/2018	1	18/05/2018	1	Withdrawn By Sponsor	Recruitment end date has been brought forward as UK target has been met. Too strict criteria
37453	16/WM/0395	210507	A phase 3 randomized, open-label (sponsor-blind), active-controlled, parallel-group, multicenter, event driven study in dialysis subjects with anemia associated with chronic kidney disease to evaluate the safety and efficacy of daprodustat compared	Number Agreed	2	2	Date Agreed	01/11/2019	2	07/06/2018	2	Withdrawn By Sponsor	Recruitment closed early
37454	16/EM/0384	182787	An Open-label, 2 x 2 Factorial, Randomized Controlled, Clinical Trial to Evaluate the Safety of Apixaban vs. Vitamin K Antagonist and Aspirin vs. Aspirin Placebo in Patients with Atrial Fibrillation and Acute Coronary Syndrome or Percutaneous Coronar	Number Agreed	5	5	Date Agreed	31/05/2018	5	11/04/2018	5	Withdrawn By Sponsor	End date closed early by sponsor as study target has been reached
37455	16/LO/1811	214264	A PHASE II, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF THE SAFETY AND EFFICACY OF GDC-0853 IN PATIENTS WITH MODERATE TO SEVERE ACTIVE SYSTEMIC LUPUS ERYTHEMATOSUS	Number Agreed	2	2	Date Agreed	01/11/2019	0	14/05/2018	0	Withdrawn By Sponsor	Sponsor closed study early. Inclusion criteria was too strict (had 3 patients who screen-failed)
37456	17/LO/0825	223457	A Randomized, Phase 2, Double-blind, Placebo-controlled Study to Assess the Safety and Efficacy of Filgotinib, GS-9876 and GS-4059 in Adult Subjects with Active Sjogren's Syndrome	Range Agreed	1	3	Date Agreed	31/01/2018	1	07/09/2018	1	Recruitment Finished	
37457	17/EE/0196	218606	Long-term observational, prospective study to collect in a real life setting data on the retention, effectiveness, safety, treatment pattern, quality of life, and efficiency of secukinumab in adult patients with moderate to severe plaque psoriasis, p	Number Agreed	8	8	Date Agreed	30/09/2018	8	30/09/2018	8	Recruitment Finished	
37614	17/LO/0085	216434	INNO2VATE – CONVERSION	Number Agreed	2	2	Date Agreed	31/12/2018	5	21/12/2018	5	Recruitment Finished	